Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
Viktor Grünwald, MD, PhD
Advertisement
Articles by Viktor Grünwald, MD, PhD
Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.
Advertisement
Latest Updated Articles
Efficacy of Lenvatinib Plus Pembrolizumab and Sunitinib in Advanced RCCPublished: June 14th 2021 | Updated:
Advice for Oncologists and Next Steps for the CLEAR Trial in RCCPublished: November 12th 2023 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
